Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9984515 | 0.92 | GPR174 (0.43) | GPR174POLBMAPTCYP1A2CYP3A4 | |
| SCHEMBL9983657 | 0.91 | GPR174 (0.45) | GPR174POLBMAPTCYP1A2CYP3A4 | |
| SCHEMBL9984710 | 0.90 | GPR174 (0.43) | GPR174POLBMAPTCYP1A2CYP3A4 | |
| SCHEMBL9985191 | 0.90 | NPSR1 (0.44) | GPR174POLBMAPTCYP1A2CYP3A4 | |
| SCHEMBL9983445 | 0.88 | ALDH1A1 (0.45) | GPR174POLBMAPTCYP1A2CYP3A4 | |
| SCHEMBL9984012 | 0.88 | MAPT (0.47) | GPR174POLBMAPTALDH1A1MEN1 | |
| SCHEMBL9984020 | 0.84 | FLT3 (0.46) | MAPTCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL9985154 | 0.84 | MAPT (0.45) | GPR174POLBMAPTCYP1A2CYP3A4 | |
| SCHEMBL9984698 | 0.84 | MAPT (0.41) | POLBMAPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9985370 | 0.84 | POLB (0.42) | GPR174POLBMAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | claimed |
| EP-2394993-A2 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2011-12-14 | — | — | EP | claimed |
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | disclosed |
| EP-2394993-A2 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2011-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | NOS3, PTMS, NOS2 | GPR174 2376/4885POLB 4384/4885MAPT 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.